IPO Update: 35 Biopharmas Provide -6.1% Average Return; New Offerings Feel Stock Market Impact

Only 16 drug developers that went public in the US during the first three quarters are trading in positive territory. While the IPO queue keeps growing, ADC Therapeutics and Monopar cite "market conditions" as they postpone their offerings.

IPO Initial Private Offering Stock Market Ticker Building 3d Illustration
35 biopharma companies raised $4.5bn, but 19 gave IPO investors a loss. • Source: Shutterstock

Biopharmaceutical innovation continues to try and meet patient needs regardless of whether stock prices are up or down, which is a good thing since most drug developers that went public in the US during the first three quarters of 2019 – raising a total of $4.53bn – are trading in negative territory. With initial public offering performance souring, and with the stock market in decline due to US trade war concerns, a pair of firms that were expected to be among the first biopharma IPOs of the fourth quarter postponed their offerings.

The average return for the 35 companies that completed IPOs through the end of September was -6.1% with 16 firms...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from Financing

More from Business

  • How A New Healthcare Dialogue Is Driving Market Access In Mexico

    Companies stand a better chance of securing public reimbursement in Mexico for innovative medicines if they understand changing approaches to healthcare. The shift means the emergence of managed entry agreements and a focus on economic impact, explains AMIIF, Mexico's research-based pharmaceutical industry association.

  • How Novartis Is Elevating CVD Outcomes, Driving ‘Personalized Access’ In APMA

    Novartis’s APMA chief outlines the company’s tailored approach to deliver long-term outcomes, novel access solutions via innovative financing options and shape the CVD disease ecosystem in the extraordinarily diverse region. Partnering to build AI infrastructure is another key prong.

  • India Rare Diseases: Court Shows Path For Policy Action, Funding, Price Issues-- Test-2

    A court order encompassing funding, drug pricing, clinical trials and overall policy implementation aspects is expected to bring about a paradigm shift in the treatment of rare diseases in India. Sarepta, Roche and Sanofi are among the key players that have been part of pricing discussions.